Mobile Health Interventions for Medication Adherence Among PLWH

• Status: Withdrawn
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Cigarette smoking remains highly prevalent among persons living with HIV (PLWH). Quitting smoking can have important health benefits for this population. However, PLWH have historically had a difficult time quitting smoking. This is likely due, at least in part, to poor medication adherence.

Poor adherence to medication is a well-documented issue among PLWH. Research shows that not taking smoking cessation medications as prescribed can limit their treatment effectiveness. Improving adherence to smoking cessation medications will likely increase smoking cessation attempt success.

Mobile phone applications and behavioral interventions show promise for improving adherence to smoking cessation medications and cessation outcomes among PLWH. Therefore, this trial will assess 1) whether a mobile phone application is a feasible and acceptable intervention for improving medication adherence; 2) whether use of the mobile phone app improves adherence to varenicline; and 3) smoking cessation outcomes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Duke University
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Varenicline

Criteria

Inclusion Criteria:

• Between the ages of 18-65

• HIV-positive

• Currently engaged with an HIV care provider

• Interested in quitting smoking within the next 30 days

• Has an Android (v5.x.x or Lollipop) or iOS (v6.0) smartphone (interested participants without a compatible smartphone will be provided one, with costs offset by the study team)

• English-speaking

• Capable of giving written informed consent

Exclusion Criteria:

• Inability to attend study sessions

• Any medical condition or concomitant medication that could compromise participant safety or treatment, as determined by the Principal Investigator, Study Physician, and/or participant's HIV care provider

• Current use of nicotine replacement therapy or other smoking cessation treatment (e.g., bupropion)

• Pregnant, planning to become pregnant, nursing, or becoming pregnant during the study

• BAL >0.000 at screening.